Toward a New Frontier in Myocardial Reperfusion Therapy
- 20 January 1998
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 97 (2), 211-218
- https://doi.org/10.1161/01.cir.97.2.211
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Glycoprotein IIb/IIIa Receptor Inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG Trials into PerspectiveThe American Journal of Cardiology, 1996
- Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarctionThe American Journal of Cardiology, 1996
- Pharmacokinetics and Pharmacodynamics of TP-9201, a gpIIbIIIa Antagonist, Administered in Combination with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin in BeaglesJournal of Cardiovascular Pharmacology, 1996
- The Stentor and the sea changeThe American Journal of Cardiology, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsThe Lancet, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- Release of Prostaglandins and Thromboxane into the Coronary Circulation in Patients with Ischemic Heart DiseaseNew England Journal of Medicine, 1981